MT-101 is under clinical development by MThera Pharma and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MT-101 overview

MT-101 is under development for the treatment of Parkinson's disease. It is administered through oral route.

MThera Pharma overview

MThera Pharma (MThera Pharma) is a biopharmaceutical company that intends to develop new medicines for chronic diseases. The company is developing its pipeline products including MT101, MT102, MT103, MT104 for the discovery of drugs targeted for multiple therapeutics such as Parkinson’s and dementia. It is a provider of a new drug that fundamentally treats diseases by using multi-component natural materials for multiple targets of chronic intractable diseases. MThera has developed expertise in a multi-component and multi-targeting (MCMT) approach with cutting-edge CMC technology to penetrate into the advanced global market. MThera Pharma is headquartered Seoul, South Korea.

For a complete picture of MT-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.